SomboonpornW, DavisS, SeifM. Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev, 2005; 4:CD004509.
2.
AchilliC, PundirJ, RamanathanP, SabatiniL, HamodaH, PanayN. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: A systematic review and meta-analysis. Fertil Steril, 2017; 107:475–482.
3.
RosenRC, ShifrenJL, MonzBU, OdomDM, RussoPA, JohannesCB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med, 2009; 6:1549–1560.
4.
ShifrenJL, MonzBU, RussoPA, SegretiA, JohannesCB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol, 2008; 112:970–978.
5.
ParishSJ, GoldsteinAT, GoldsteinSW, GoldsteinI, PfausJ, ClaytonAH, et al.Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—Part II. J Sex Med, 2016; 13:1888–1906.
6.
GoldsteinI, KimNN, ClaytonAH, DeRogatisLR, GiraldiA, ParishSJ, et al.Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc, 2017; 92:114–128.
7.
Addyi (flibanserin) prescribing information. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC, 2018.
8.
KingsbergSA, ClaytonAH, PfausJG. The female sexual response: Current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs, 2015; 29:915–933.
9.
PfausJ, GiulianoF, GelezH. Bremelanotide: An overview of preclinical CNS effects on female sexual function. J Sex Med, 2007; 4(Suppl. 4):269–279.
10.
PfausJG, ShadiackA, Van SoestT, TseM, MolinoffP. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A, 2004; 101:10201–10204.
11.
MolinoffPB, ShadiackAM, EarleD, DiamondLE, QuonCY. PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci, 2003; 994:96–102.
12.
NappiRE, PalaciosS, BruyniksN, ParticcoM, PanayN, investigatorsES. The burden of vulvovaginal atrophy on women's daily living: Implications on quality of life from a face-to-face real-life survey. Menopause, 2019; 26:485–491.
13.
SantoroN, KomiJ. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med, 2009; 6:2133–2142.
14.
GliniewiczK, SchneiderGM, RidenhourBJ, et al.Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front Microbiol, 2019; 10:193.
15.
KingsbergSA, KrychmanML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med, 2013; 10:1567–1574.
16.
KrychmanM, GrahamS, BernickB, MirkinS, KingsbergSA. The women's EMPOWER survey: Women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med, 2017; 14:425–433.
